timothy sykes logo
TVTX Stock Jumps As FILSPARI Wins Full FDA Approval Thumbnail
ADD US ONG Google News

TVTX Stock Jumps As FILSPARI Wins Full FDA Approval

BRYCE TUOHEY•UPDATED APR. 14, 2026, 11:32 AM ET
Reviewed by Tim Sykes Fact-checked by Matt Monaco

Travere Therapeutics Inc. stocks have been trading up by 33.88 percent, driven largely by impactful FDA-related advancement news.

Candlestick Chart

Live Update At 11:32:26 EDT: On Tuesday, April 14, 2026 Travere Therapeutics Inc. stock [NASDAQ: TVTX] is trending up by 33.88%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TVTX has been trading like a classic catalyst name. On 2026/04/13, the stock closed at $30.70. One day later, after the FDA news, Travere Therapeutics finished at $41.10. That is a massive one‑day repricing and a clear sign the market is baking in a much bigger future for FILSPARI.

Zooming out, TVTX had been grinding higher from late March, moving from the high‑$20s into the low‑$30s before the gap. That slow stair‑step higher told traders that smart money was already positioning for a positive decision. The intraday 5‑minute chart on 2026/04/14 shows heavy volatility out of the open, with TVTX spiking to $42.50 premarket, then chopping between roughly $40 and $42 through the morning. That’s a textbook high‑volume catalyst day.

Fundamentally, Travere Therapeutics is still a high‑growth, money‑losing biotech. Revenue in the latest quarter was about $129.7M, with gross margin near 98%, but operating income was negative at roughly -$32.4M. TVTX burns cash on R&D and G&A, yet it also generated about $60.7M in operating cash flow and $41.4M in free cash flow thanks to working‑capital moves. With around $322.8M in cash and short‑term investments and a current ratio of 2.7, TVTX has room to keep funding commercialization while traders focus on top‑line growth.

Why Traders Are Watching TVTX After FDA Win

TVTX is front and center on many trading screens because this is not a small label tweak. Travere Therapeutics just turned FILSPARI into a first‑in‑class standard for focal segmental glomerulosclerosis, or FSGS, in adults and kids 8 and older without nephrotic syndrome. That matters. FSGS is rare, serious, and had no approved targeted drug. Now FILSPARI fills that gap.

For traders, the key number is reach. Travere Therapeutics already had an IgA nephropathy indication. With the new FSGS approval, TVTX now targets a combined U.S. addressable population of more than 100,000 patients, including an estimated 30,000 FSGS patients. In rare‑disease land, 30,000 is not small. It is a meaningful, model‑able revenue leg that sits on top of the existing franchise.

The Street was lining up ahead of this move. Citi kept a Buy rating on TVTX with a $48 price target and even put Travere Therapeutics on an “upside 90‑day catalyst watch,” saying the market was underestimating the FSGS decision. The catalyst has now landed, validating that thesis and giving momentum traders a narrative they can lean into.

JPMorgan did trim its TVTX target from $44 to $41, but the firm stayed Overweight. That tells traders this is a recalibration, not a rug‑pull. Add in the earlier 9.5% rally to $33.33 without a defined catalyst, and you get a picture of a stock that was already coiled. The FDA win simply released that tension. For active traders, TVTX is now a live case study in how regulatory catalysts reshape a small‑cap biotech’s chart almost overnight.

More Breaking News

Conclusion

Travere Therapeutics has crossed a major threshold with FILSPARI’s full FDA approval in FSGS, and TVTX is trading like it. The stock ripped from the low‑$30s into the low‑$40s as the market quickly repriced the expanded label and the larger rare‑kidney footprint. For traders, the story is simple to frame: first‑and‑only drug status, a combined 100,000‑plus U.S. patient pool, and Street targets that still sit above the latest close.

The fundamentals are not all clean. TVTX still posts negative margins, heavy R&D spend, and a leveraged balance sheet. But Travere Therapeutics also has strong gross margins, solid liquidity, and a commercial asset that just gained a second, high‑value indication. That combination is exactly what momentum‑oriented biotech traders look for: real news, real revenue potential, and a chart that responds.

TVTX now becomes a textbook watchlist name for those who trade catalysts and volatility. As Tim Sykes likes to say, “The pattern repeats, but the tickers change.” As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. Travere Therapeutics is the latest ticker running that pattern — big news, big gap, big opportunity for prepared traders who study the price action, manage risk, and never chase blindly. This article is for educational and research purposes only, but for disciplined chart‑watchers, TVTX offers a live lesson in how news, sentiment, and price can align.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TVTX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”